Physician profile
Robert Occhipinti
NPI 1023112679
$4,491.37
in general payments reported to CMS, 2019-2025
36 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $92.55 · 2021: $71.01 · 2022: $834 · 2023: $674 · 2024: $983 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $639.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $370.83 | 2022-2025 | |
| Abbvie INC. | $343.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $342.09 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Viiv Healthcare Company | $320.13 | 2022-2025 | Apretude, Cabenuva |
| Novo Nordisk INC | $314.65 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $310.74 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $286.96 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Amgen INC. | $226.58 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.40 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $130.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $118.13 | 2019-2022 | |
| Theratechnologies INC. | $116.34 | 2022-2025 | Egrifta, Trogarzo |
| Gilead Sciences, INC. | $92.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $80.01 | 2019-2023 | Eliquis |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Occhipinti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.